跳至主要内容
临床试验/NCT02038322
NCT02038322已完成不适用

The Stork™ Conception System (OTC) Clinical Trial: Semen Collection, Placement and Delivery

Rinovum Women's Health, Inc.2 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2013年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
53
试验地点
2
主要终点
Efficacy -Primary endpoint part 1 - Collection

研究概览

简要总结

This is a clinical study designed to validate the usability and safety of the over-the-counter (OTC) device by obtaining feedback in a home use environment regarding ease of use of The Stork™ Conception System and the instructions for use. In addition to usability, results for safety, including vaginal

详细描述

Female participants will undergo a baseline pelvic examination. Participating couples will be given The Stork™ Conception System (OTC), including Instructions for Use, the questionnaire and two ziplock bags. The device will be used in accordance with the instructions for use. Participants will use the Conceptacle as a collection condom during sexual intercourse. Participants will remove the Cervical Cap from the Sheath of the Conceptacle and discard the Sheath. Participants will then load the Cervical Cap into the Applicator for insertion, placement and deployment of the device. Participants will wash the applicator with soap and water and place it in the double zip lock bags. During the time the cervical cap is inserted, normal activity will be recommended with the exception of having intercourse. The female participants will leave the conception cap inserted for a period of time between 4 and 12 hours, return to the investigator's office for examination, remove the Cervical Cap, and undergo a follow up pelvic examination. Participants will be asked to complete the study and the questionnaire within 3 days of receiving the study packet. As a result, this study could take up to 4 days to complete per enrolled couple.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Literacy must be in English (able to understand Informed Consent)
  • In general good health
  • Heterosexual, monogamous couples, of any race or ethnicity, who are sexually active (as a couple)
  • 18 - 50 years of age
  • REALM-SF Test Results demonstrate 6th grade literacy or above
  • Past experience with using condoms
  • Trying to conceive or using a non-vaginal birth control with which they do not normally use a condom.
  • Signed Informed Consent

排除标准

  • Vaginal prolapsed (female)
  • Hysterectomy (female)
  • Erectile Dysfunction (male)
  • Colposcopy with biopsy surgery within the last three (3) months (female)
  • Treatment for dysplasia surgery within the last three (3) months (female)
  • Vaginal/cervical surgery within the last three (3) months (female)
  • Current Pregnancy (female)
  • Unable to read and understand English

结局指标

主要结局

Efficacy -Primary endpoint part 1 - Collection

时间窗: 1-3 days

The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. The three parts of the endpoint are: P1: Participants indicate ability to collect and contain semen using the Conceptacle™. The examinations will occur 4-12 hours after device insertion.

Efficacy - Primary endpoint part 2 - Placement

时间窗: 4-12 hrs

The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. P2: Successful placement of the cervical cap as determined by physical examination.

Primary endpoint part 3 -Safety

时间窗: 4-12 hrs

The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. P3: Participants use the device without any evidence of damage to the female participants' genital tract as depicted by physician examination.

次要结局

  • Secondary Endpoint(up to 3 days)

研究者

发起方
Rinovum Women's Health, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验